Overview

A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia

Status:
Active, not recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

Study 111-206 is a Phase 2 randomized, double-blind, placebo-controlled clinical trial of BMN 111 in infants and young children with a diagnosis of Achondroplasia.

Phase:

Phase 2

Details

Lead Sponsor:

BioMarin Pharmaceutical

Treatments:

Natriuretic Peptide, C-Type